Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib Plus Fulvestrant in HR+/HER2+ Metastatic Breast Cancer
NCT04033172Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Nov 2018
- Primary completion
- Mar 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04033172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04033172.